Skip to main content

Table 4 Univariate and multivariate cox regression analyses of OS in BCLM patients

From: Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population

Univariable analysis

Multivariable analysis

Characteristic

Hazard ratio (95% CI)

p value

Characteristic

Hazard ratio (95% CI)

p value

Age

  

Age

  

< 50

Reference

 

< 50

  

≥50

1.04 (0.86, 1.25)

0.715

≥50

  

ECOG

  

ECOG

  

0

Reference

 

0

Reference

 

1

1.23 (0.96, 1.59)

0.099

1

1.13 (0.87, 1.46)

0.351

2

2.62 (1.71, 4.01)

< 0.001

2

1.75 (1.12, 2.73)

0.015

Pathological type

     

IDC

Reference

    

ILC

0.97 (0.53, 1.76)

0.912

   

Others

0.79 (0.49, 1.27)

0.324

   

T-stage

  

T-stage

  

T1

Reference

 

T1

Reference

 

T2

1.17 (0.92, 1.47)

0.197

T2

1.05 (0.83, 1.34)

0.682

T3

1.51 (1.01, 2.26)

0.044

T3

1.10 (0.72, 1.69)

0.654

T4

1.41 (0.94, 2.11)

0.095

T4

1.11 (0.70, 1.76)

0.654

Unknown

0.93 (0.70, 1.24)

0.625

Unknown

0.98 (0.70, 1.37)

0.896

N-stage

  

N-stage

  

N0

Reference

 

N0

Reference

 

N1

1.17 (0.90, 1.52)

0.241

N1

1.05 (0.80, 1.38)

0.719

N2

1.34 (1.01, 1.77)

0.045

N2

1.06 (0.78, 1.44)

0.708

N3

1.79 (1.36, 2.36)

< 0.001

N3

1.26 (0.91, 1.74)

0.165

Unknown

1.19 (0.84, 1.69)

0.330

Unknown

1.01 (0.65, 1.55)

0.977

M-stage

     

M0

Reference

    

M1

1.15 (0.89, 1.49)

0.296

   

Subtype

  

Subtype

  

HR+/HER2-

Reference

 

HR+/HER2-

Reference

 

HR−/HER2+

1.43 (1.08, 1.90)

0.013

HR−/HER2+

1.35 (1.00, 1.83)

0.051

HR+/HER2+

1.04 (0.79, 1.37)

0.769

HR+/HER2+

1.04 (0.78, 1.38)

0.788

Triple-negative

1.73 (1.36, 2.19)

< 0.001

Triple-negative

1.76 (1.36, 2.29)

< 0.001

Liver metastases

  

Liver metastases

  

No

Reference

 

No

Reference

 

Yes

2.71 (2.20, 3.35)

< 0.001

Yes

2.19 (1.70, 2.82)

< 0.001

Brain metastases

     

No

Reference

    

Yes

1.40 (0.94, 2.10)

0.100

   

Bone metastases

  

Bone metastases

  

No

Reference

 

No

Reference

 

Yes

1.43 (1.18, 1.74)

< 0.001

Yes

1.13 (0.88, 1.44)

0.344

Number of metastatic sites

  

Number of metastatic sites

  

1

Reference

 

1

Reference

 

2

1.86 (1.44, 2.40)

< 0.001

2

1.76 (1.34, 2.31)

< 0.001

≥3

2.42 (1.89, 3.09)

< 0.001

≥3

1.74 (1.24, 2.44)

0.001

DFS

  

DFS

  

≤2 years

Reference

 

≤2 years

Reference

 

> 2 years

0.59 (0.48, 0.72)

< 0.001

> 2 years

0.66 (0.53, 0.83)

< 0.001

M1

0.81 (0.61, 1.08)

0.147

M1

0.76 (0.55, 1.06)

0.105

First-line therapy

  

First-line therapy

  

Single-agent chemotherapy

Reference

 

Single-agent chemotherapy

Reference

 

Combination therapy

0.71 (0.47, 1.07)

0.099

Combination therapy

0.69 (0.46, 1.05)

0.085

Endocrine therapy

0.43 (0.25, 0.75)

0.003

Endocrine therapy

0.70 (0.39, 1.25)

0.223

  1. OS overall survival, BCLM breast cancer lung metastases, CI confidence interval, ECOG Eastern Cooperative Oncology Group, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, HR hormone receptor, HER2 human epidermal growth factor receptor 2, DFS disease-free survival
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us